Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: UL stock price vs BSX: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at BSX's multiple
Needs Annual EPS, BSX P/E.
Implied fair value · at UL's multiple
Needs Annual EPS, UL P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Higher is better
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
UNILEVER PLC · implied price per share
Reporting currency could not be verified.
BOSTON SCIENTIFIC CORP · implied price per share
Reporting currency could not be verified.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
UL · not enough data.
BSX · not enough data.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
PROCTER & GAMBLE Co
UL vs PG
COLGATE PALMOLIVE CO
UL vs CL
JOHNSON & JOHNSON
UL vs JNJ
KIMBERLY CLARK CORP
UL vs KMB
CHURCH & DWIGHT CO INC /DE/
UL vs CHD
Abbott Laboratories
UL vs ABT
Intuitive Surgical, Inc.
UL vs ISRG
STRYKER CORP
UL vs SYK
ZIMMER BIOMET HOLDINGS, INC.
UL vs ZBH
Edwards Lifesciences Corp
UL vs EW
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe UL can reaccelerate growth and sustain its current margin profile while keeping leverage contained, then UL can be justified as a value play versus BSX because it trades at a much lower P/E and P/S multiple; if not, the weaker growth and higher net debt/EBITDA argue for caution.
On a P/E basis, UL trades at 12.8x versus BSX at 24.1x, which drives the large implied upside to $119.79 from UL's current $63.41. However, the market is already pricing UL within its historical band, and the DCF range is materially below the current price, suggesting the headline upside is not fully supported by intrinsic value work.
Supporting Metrics
